COMP <GO>
LXEO vs CABA // NET PROFIT MARGIN
Lexeo Therapeutics Inc. (NASDAQ) VS. Cabaletta Bio Inc. (NASDAQ) • 15-METRIC TALLY: LXEO 2
— CABA 0
■ METRIC PARITY
LAST: $3.06 (-2.55%) • MKT CAP: $257.6M
net-margins
—
LAST: $1.43 (-5.30%) • MKT CAP: $256.0M
net-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LXEO VS. CABA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LXEO | CABA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.6 | 38.6 | +10.00 | LXEO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $257.6M | $256.0M | $1.6M | LXEO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LXEO REV | CABA REV | LXEO GROSS % | CABA GROSS % | LXEO FCF | CABA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $305.9M | $482.3M | — | — | -$99.0M | -$132.3M |
| FY 2024 | $296.1M | $350.4M | — | — | -$81.6M | -$90.4M |
| FY 2023 | $191.8M | $209.0M | — | — | -$59.5M | -$53.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LXEO // BETA —
CABA // BETA —